New immunisation reference page: Neutropenia: Vaccine recommendations for children with chronic neutropenia
Children with neutropenia are at increased risk of bacterial and fungal infections and therefore preventing infections in this group is a priority in order to protect these children against vaccine preventable diseases (VPDs). However, this patient group is not addressed in The Australian Immunisation Handbook.
Our new reference page, Neutropenia: vaccine recommendations for children with chronic neutropenia discusses the recommendations for this group based on international guidelines and local consensus.
अधिक पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
MVEC: New immunisation reference page: Neutropenia: Vaccine recommendations for children with chronic neutropenia
12-17 वर्ष आयु वर्ग को शामिल करने के लिए आधुनिक COVID-19 वैक्सीन का TGA अनंतिम अनुमोदन
4 सितंबर 2021 को थेराप्यूटिक गुड्स एडमिनिस्ट्रेशन (TGA) ने दी अस्थायी स्वीकृति 12-17 वर्ष आयु वर्ग को शामिल करने के लिए अपने COVID-19 वैक्सीन- स्पाइकवैक्स (इलासोमेरन) के लिए मॉडर्न ऑस्ट्रेलिया पीटीवाई लिमिटेड को। यह निर्णय 18 वर्ष और उससे अधिक आयु के व्यक्तियों में उपयोग के लिए 9 अगस्त 2021 को स्पाइकवैक्स को टीजीए द्वारा दी गई अनंतिम स्वीकृति के बाद लिया गया है।
अधिक जानकारी प्राप्त करने के लिए, कृपया नीचे दिए गए लिंक में हमारे समर्पित MVEC Moderna COVID-19 टीकाकरण पृष्ठ देखें:
एमवीईसी मॉडर्न कोविड-19 टीकाकरण पृष्ठ
New immunisation reference page: Immune thrombocytopenia (ITP)
Immune thrombocytopenia, also previously known as idiopathic thrombocytopenia purpura (ITP), is an uncommon autoimmune condition in which the body’s own immune system attacks platelets (the cells found in the blood which normally help the blood to clot).
Our new reference page discusses the background of ITP, including presentation of the condition and the association between ITP and MMR vaccines. Our page also answers questions around ITP and COVID-19 vaccines, including whether or not COVID-19 vaccines should be administered to people with a history of ITP.
अधिक पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
MVEC: Immune thrombocytopenia (ITP)
30 अगस्त सीवीयू मिनी की रिकॉर्डिंग अब उपलब्ध है
हमारे हालिया सीवीयू मिनिसरीज इवेंट में भाग लेने वाले सभी लोगों को धन्यवाद दिल के मामले: COVID-19 mRNA टीकाकरण से जुड़े मायोकार्डिटिस और पेरिकार्डिटिस on 30th August 2021.
This interactive webinar took an in-depth look at an important vaccine safety signal associated with COVID-19 mRNA vaccines (Pfizer and Moderna).
इस घटना की एक रिकॉर्डिंग अब हमारे शिक्षा पोर्टल के माध्यम से उपलब्ध है।
इस रिकॉर्डिंग तक पहुँचने के लिए कृपया नीचे दिए गए लिंक का अनुसरण करें:
The Age: ‘The moment you walk in through those doors your healing starts’: Victoria leading the race on Indigenous vaccination
Data released by the federal government has highlighted the widening gap between fully vaccinated Indigenous Australians and the overall population, and the direct impact COVID-19 will have on First Nations people if Australia eases restrictions once 70 or 80 per cent of adults are vaccinated.
Historically, Australia’s Aboriginal community has been heavily impacted by the effects of widespread viral infections such as measles, smallpox and the Spanish Flu and this article highlights the impact low COVID-19 vaccination rates could have on our First Nations people.
Despite the slow rollout, Victoria is leading the way in terms of vaccination rates amongst the Indigenous population with 43% of people fully vaccinated against COVID-19, more than double that of the non-Indigenous population in Victoria at 26%.
According to Jeroen Weimar, the COVID-19 response commander in Victoria, the states’ success with facilitating a competent roll out initiative amongst the Indigenous communities can be attributed to joint efforts and strong partnerships.
लेख को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें।
The Age: ‘The moment you walk in through those doors your healing starts’: Victoria leading the race on Indigenous vaccination
WHO: Safety profile of nOPV2 vaccine
In an attempt to implement a global eradication initiative of the polio virus, the first type 2 novel oral polio vaccine (nOPV2) became the first vaccine to be authorised for use under the WHO Emergency Use Listing (EUL) apparatus. However, the current nOPV2 vaccine presents an increased risk of type 2 circulating vaccine-derived polioviruses (cVDPV2), especially in communities with low immunization rates. African countries continue to be amongst the most impacted by this potentially lethal virus. Consequentially, the use of the nOPV2 is currently restricted and SAGE recommended that an independent safety monitoring group be established (GACVS) and maintain thorough safety observations during the entire period of the EUL.
Under the current EUL, there is a 2 phase roll out of the nOPV2 vaccine. With phase 1, countries must first meet stringent initial use criteria and verification requirements including continuous flaccid paralysis (AFP) monitoring to attain approval for use. Following this, phase 2 supports the use of the nOPV2 vaccine as a standard response for cVDPV2 outbreaks.
Following rigorous safety criteria, as of 9 June 2021, 7 countries have received approval for use authorisation of the nOPV2 vaccine and 25 countries are still pending. Majority of the nOPV2 doses thus far have been administered in Nigeria (17 899 130) and Liberia (853 279) amongst children 5 years of age and under in the form of two oral vaccine drops. GACVS is working closely with the Liberian and Nigerian governments to implement AESI surveillance and ongoing AFP data to ensure the safety and effectiveness of the vaccine in preventing polio infection. Current preliminary data analysis did not indicate elevated safety issues associated with the nOPV2 vaccine, however GACVS members have stressed that prolonged, comprehensive surveillance is imperative to signal imminent safety concerns.
To read the extract in full, please click on the link below:
WHO: Safety profile of nOPV2 vaccine
एबीसी न्यूज यूएस: अधिकारी का कहना है कि एफडीए द्वारा अनुमोदित फाइजर वैक्सीन बच्चों में ऑफ-लेबल उपयोग के लिए ठीक नहीं है
अमेरिकी खाद्य एवं औषधि प्रशासन (एफडीए) ने 16 वर्ष से अधिक उम्र के लोगों के लिए फाइजर कोविड-19 वैक्सीन की पूर्ण मंजूरी के बाद सलाह जारी की है कि इसे छोटे बच्चों को ऑफ-लेबल उपयोग के रूप में नहीं दिया जाना चाहिए।
Pfizer's COVID-19 vaccine was 12 से 15 वर्ष की आयु के बच्चों में उपयोग के लिए अधिकृत मई में एफडीए द्वारा, ईयूए में संशोधन के सभी मानदंडों को पूरा करते हुए और 12-15 आयु वर्ग के बच्चों में 1001टीपी3टी प्रभावशीलता के साथ। इसके अतिरिक्त, मॉडर्ना और जॉनसन एंड जॉनसन दोनों टीके अमेरिका में 18 वर्ष और उससे अधिक उम्र के किसी भी व्यक्ति के लिए उपलब्ध हैं, मॉडर्ना अभी भी एफडीए के साथ आपातकालीन उपयोग प्राधिकरण पर अनुमोदन के निर्णय का इंतजार कर रही है।
5-11 साल के बच्चों पर फाइजर वैक्सीन सुरक्षा डेटा सितंबर के अंत तक प्रस्तुत किया जाना है, मॉडर्ना की रिपोर्ट गिरावट के बीच में आने वाली है। क्लिनिकल परीक्षण अभी भी चल रहे हैं, हालांकि, यह उम्मीद की जाती है कि 5-11 वर्ष की आयु के बच्चों के लिए पहला टीका 2021 के अंत तक या 2022 की शुरुआत में हो सकता है। रोल आउट शुरू होने से पहले दुर्लभतम दुष्प्रभावों का पता लगाने के लिए अमेरिका, एफडीए ने सलाह दी है कि परीक्षणों के लिए स्वयंसेवकों के पूल का विस्तार करने की आवश्यकता होगी।
लेख को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें
एबीसी न्यूज यूएस: अधिकारी का कहना है कि एफडीए द्वारा अनुमोदित फाइजर वैक्सीन बच्चों में ऑफ-लेबल उपयोग के लिए ठीक नहीं है
MVEC animation: Myocarditis, pericarditis and COVID-19 vaccines
MVEC have created a new animation to help explain myocarditis and pericarditis which have been reported in a small number of individuals who have received mRNA कोविड-19 टीके Comirnaty™ और Moderna.
To view the animation and to find out more information, please refer to our myocarditis, pericarditis following COVID-19 mRNA vaccines immunisation reference page:
MVEC animation: Myocarditis and pericarditis following COVID-19 mRNA vaccines
Federal Government Announces No Fault COVID-19 Indemnity Scheme
Federal Health Minister Greg Hunt has announced the details of the no fault COVID-19 Vaccine Claim Scheme following extensive consultation with the peak medical, healthcare, business and insurance sectors to ensure a comprehensive National Scheme.
The purpose of the Scheme will be to provide Australians with quick access to compensation for COVID-19 claims related to the administration of a Therapeutic Goods Administration approved COVID-19 vaccine delivered through a Commonwealth Government approved program.
From 6 September Australians who suffer injury and loss of income due to their COVID-19 vaccine will be able to register their intent to claim from the COVID-19 vaccine claims scheme webpage.
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
Federal Government Announcement: No Fault COVID-19 Indemnity Scheme
ATAGI recommendations on the use of COVID-19 vaccines in all young adolescents in Australia
The Australian Technical Advisory Group on Immunisation (ATAGI) has released recommendations on the use of COVID-19 vaccines in all young adolescents in Australia.
The advice recommends children aged 12-15 be vaccinated against COVID-19 using Comirnaty (Pfizer).
A summary of ATAGI recommendations includes:
- Vaccination against COVID-19 is recommended for all individuals from 12 years of age, extending the current recommendation for those aged 16 years and older.
- A two-dose schedule using Comirnaty (Pfizer), the only vaccine currently registered for use in Australia in this age group, is recommended.
- Recommendations on the use of Spikevax (Moderna) for adolescents will be finalised following the decision on provisional registration of Spikevax (Moderna) in this age group.
To read the statement in full, please click the link below:
ATAGI recommendations on the use of COVID-19 vaccines in all young adolescents in Australia